Clinuvel Pharmaceuticals Ltd
ASX:CUV
Clinuvel Pharmaceuticals Ltd
Total Liabilities
Clinuvel Pharmaceuticals Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Liabilities
AU$20.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Liabilities
$187.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Total Liabilities
$19.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Liabilities
AU$1.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Liabilities
AU$748.6m
|
CAGR 3-Years
62%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Liabilities
AU$11.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
27%
|
CAGR 10-Years
30%
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Total Liabilities?
Total Liabilities
20.7m
AUD
Based on the financial report for Dec 31, 2025, Clinuvel Pharmaceuticals Ltd's Total Liabilities amounts to 20.7m AUD.
What is Clinuvel Pharmaceuticals Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
23%
Over the last year, the Total Liabilities growth was 9%. The average annual Total Liabilities growth rates for Clinuvel Pharmaceuticals Ltd have been -1% over the past three years , 16% over the past five years , and 23% over the past ten years .
